Literature DB >> 3197750

Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.

G T Blyden1, D J Greenblatt, B W LeDuc, J M Scavone.   

Abstract

Pharmacokinetic interactions between antipyrine and acetaminophen were evaluated in 7 healthy volunteers. On 3 occasions subjects received: 1, antipyrine 1.0 g intravenously (i.v.); 2, acetaminophen 650 mg i.v.; 3, antipyrine 1.0 g and acetaminophen 650 mg i.v. simultaneously. Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly. Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced. Eight additional subjects received 50 mg of lidocaine hydrochloride i.v. in the control state, and on a second occasion immediately after antipyrine 1.0 g given i.v. The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1). Although acetaminophen does not alter antipyrine kinetics, acute administration of antipyrine appears to impair acetaminophen clearance, possibly via inhibition of glucuronide formation. However, antipyrine has no significant effect on the kinetics of a single i.v. dose of lidocaine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197750     DOI: 10.1007/bf00561374

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 3.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Simultaneous determination of lidocaine and its deethylated metabolites using gas-liquid chromatography with nitrogen-phosphorus detection.

Authors:  C R Willis; D J Greenblatt; D M Benjamin; D R Abernethy
Journal:  J Chromatogr       Date:  1984-04-13

5.  Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.

Authors:  M B Penno; E S Vesell
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

6.  Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

Review 7.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

8.  Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking.

Authors:  K W Bock; J Wiltfang; R Blume; D Ullrich; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R I Shader
Journal:  J Lab Clin Med       Date:  1983-06

10.  Large theophylline requirements due to high theophylline clearance: verification by the antipyrine test.

Authors:  G T Blyden; B W LeDuc; D J Greenblatt
Journal:  Pharmacology       Date:  1986       Impact factor: 2.547

View more
  1 in total

1.  Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.

Authors:  Yanli Zhao; Jerold S Harmatz; Carol R Epstein; Yukako Nakagawa; Chie Kurosaki; Tetsuro Nakamura; Takumi Kadota; Dennis Giesing; Michael H Court; David J Greenblatt
Journal:  Br J Clin Pharmacol       Date:  2015-06-08       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.